BridgeBio Oncology Therapeutics, Inc. (BBOT)
| Market Cap | 163.56M -83.3% |
| Revenue (ttm) | n/a |
| Net Income | -182.11M |
| EPS | -2.56 |
| Shares Out | 80.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 687,045 |
| Open | 2.190 |
| Previous Close | 2.170 |
| Day's Range | 1.980 - 2.250 |
| 52-Week Range | 1.980 - 14.870 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 23.55 (+1,054.41%) |
| Est. Earnings | Nov 20, 2026 |
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for BBOT stock is "Strong Buy." The 12-month stock price target is $23.55, which is an increase of 1,054.41% from the latest price.
News
BridgeBio Oncology price target lowered to $13 from $18 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BridgeBio Oncology (BBOT) to $13 from $18 and keeps an Overweight rating on the shares.
BridgeBio Oncology price target lowered to $16 from $22 at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed lowered the firm’s price target on BridgeBio Oncology (BBOT) to $16 from $22 and keeps an Outperform rating on the shares. The firm believes the September…
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignan...
BridgeBio Oncology Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China's rapid drug development is reshaping competition, but innovation remains crucial. AI integration is accelerating research and reducing costs. The pipeline is reprioritized toward high-value indications, with key data readouts expected in Q4 and mid-2027. Cash runway extends into 2028.
JPMorgan cuts BridgeBio target, sees buying opportunity on selloff
JPMorgan lowered the firm’s price target on BridgeBio Oncology (BBOT) to $23 from $25 and keeps an Overweight rating on the shares. The firm updated the company’s model following the…
BridgeBio Oncology price target lowered to $27 from $39 at Leerink
Leerink analyst Andrew Berens lowered the firm’s price target on BridgeBio Oncology (BBOT) to $27 from $39 and keeps an Outperform rating on the shares. The firm notes BridgeBio has…
BridgeBio Oncology price target lowered to $22 from $24 at Raymond James
Raymond James analyst Sean McCutcheon lowered the firm’s price target on BridgeBio Oncology (BBOT) to $22 from $24 and keeps an Outperform rating on the shares. BridgeBio’s strategic reprioritization ...
BridgeBio Oncology price target lowered to $15 from $23 at Stifel
Stifel lowered the firm’s price target on BridgeBio Oncology (BBOT) to $15 from $23 and keeps a Buy rating on the shares after the company announced a pipeline reprioritization and…
BridgeBio Oncology price target lowered to $20 from $23 at Canaccord
Canaccord lowered the firm’s price target on BridgeBio Oncology (BBOT) to $20 from $23 and keeps a Buy rating on the shares. The firm updated its model after the company…
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway maligna...
BridgeBio Oncology Therapeutics Slides: Corporate presentation
BridgeBio Oncology Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
BBOT to Participate in Upcoming Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway maligna...
BridgeBio Oncology Therapeutics Registration statement: Registration filing
BridgeBio Oncology Therapeutics filed a registration statement on September 1, 2026, providing details about a securities offering with the SEC.
BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan
JPMorgan analyst Priyanka Grover lowered the firm’s price target on BridgeBio Oncology (BBOT) to $25 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s…
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO...
BridgeBio Oncology Therapeutics Earnings release: Q2 2026
BridgeBio Oncology Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
BridgeBio Oncology Therapeutics Quarterly report: Q2 2026
BridgeBio Oncology Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
BridgeBio Oncology initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of BridgeBio Oncology (BBOT) with an Overweight rating and $27 price target Initial phase 1 data readouts from the BBO-8520, BBO-11818, and BBO-10203 programs provide “earl...
BridgeBio Oncology assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of BridgeBio Oncology (BBOT) with an Outperform rating and $22 price target The oncology pipeline is viewed as differentiated across multiple RAS-targeted programs, led by...
BridgeBio Oncology Therapeutics Transcript: AGM 2026
Shareholders approved the election of two directors and ratified Deloitte & Touche as auditor for 2026. No questions were raised, and all proposals passed with the required majority. Final results will be reported in meeting minutes and SEC filings.
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignanc...
BridgeBio Oncology Therapeutics Earnings release: Q1 2026
BridgeBio Oncology Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
BridgeBio Oncology Therapeutics Quarterly report: Q1 2026
BridgeBio Oncology Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
BridgeBio Oncology initiated with a Buy at Canaccord
Canaccord initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target The company is developing RAS inhibitors positioned for effective and tolerable combinations, the analy...
BridgeBio Oncology initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $23 price target